Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Source: SeekingAlpha
2025-08-06 18:02:37 ET
In early to mid-2024, it appeared sales of Aurinia Pharmaceuticals Inc.'s ( AUPH ) Lupkynis might have topped out, and the stock was at lows below $5. When Q1 '24 earnings confirmed a resumption of sales growth in May 2024, I switched from Hold to a Buy , and the name is up about 117% since that article. I've continued to rate the name a Buy along the way, most recently in April 2025, anticipating sales of Lupkynis to continue to increase....
Read the full article on Seeking Alpha
For further details see:
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Inc
NASDAQ: AUPH
AUPH Trading
-3.33% G/L:
$13.94 Last:
400,778 Volume:
$14.43 Open:
AUPH Latest News
AUPH Stock Data
$1,932,123,392
126,527,384
2.24%
102
N/A
Biotechnology & Life Sciences
Healthcare
CA
Edmonton
